Treatment with Soluble Fas Ligand VivoDisease-Mediating Human T Cells by Ex Selective Reduction of Graft-versus-Host

[1]  V. Boussiotis,et al.  CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  W. Murphy,et al.  Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.

[3]  T. Huizinga,et al.  Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells , 2007, European journal of immunology.

[4]  Y. Heike,et al.  Monitoring of WT1‐specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation , 2006, International journal of cancer.

[5]  R. Krance,et al.  Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. , 2006, Blood.

[6]  K. Rezvani,et al.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. , 2006, Blood.

[7]  C. Civin,et al.  Ex Vivo Soluble Fas Ligand Treatment of Donor Cells to Selectively Reduce Murine Acute Graft Versus Host Disease , 2006, Transplantation.

[8]  W. Klapper,et al.  Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation , 2006, Bone Marrow Transplantation.

[9]  A. Rudensky,et al.  Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Barrett,et al.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. , 2005, Blood.

[11]  E. Mittendorf,et al.  Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides , 2005, Breast Cancer Research and Treatment.

[12]  P. Krammer,et al.  Cutting Edge: In Contrast to Effector T Cells, CD4+CD25+FoxP3+ Regulatory T Cells Are Highly Susceptible to CD95 Ligand- but Not to TCR-Mediated Cell Death1 , 2005, The Journal of Immunology.

[13]  Matthias Edinger,et al.  Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.

[14]  A. Hanash,et al.  Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. , 2005, Blood.

[15]  R. Champlin,et al.  Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. , 2004, Blood.

[16]  M. Kotb,et al.  Human Lymphoid and Myeloid Cell Development in NOD/LtSz-scid IL2Rγnull Mice Engrafted with Mobilized Human Hemopoietic Stem Cells 12 , 2004, The Journal of Immunology.

[17]  D. Couriel,et al.  Acute graft‐versus‐host disease: Pathophysiology, clinical manifestations, and management , 2004, Cancer.

[18]  N. Longo,et al.  Dendritic cell differentiation potential of mouse monocytes: monocytes represent immediate precursors of CD8- and CD8+ splenic dendritic cells. , 2004, Blood.

[19]  N. Chao,et al.  Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. , 2004, Blood.

[20]  B. Blazar,et al.  Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation. , 2004, Blood.

[21]  D. Scheinberg,et al.  A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. , 2004, Blood.

[22]  Stephen C. Jones,et al.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. , 2003, The Journal of clinical investigation.

[23]  D. Klatzmann,et al.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. , 2003, The Journal of clinical investigation.

[24]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[25]  A. Hagenbeek,et al.  A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. , 2003, Blood.

[26]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[27]  Stephen C. Jones,et al.  Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  Els Goulmy,et al.  Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Collins,et al.  Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Mamoru Ito,et al.  NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. , 2002, Blood.

[31]  Catherine J. Wu,et al.  Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[33]  M. Papiernik,et al.  Modulation of Fas-Dependent Apoptosis: A Dynamic Process Controlling Both the Persistence and Death of CD4 Regulatory T Cells and Effector T Cells1 , 2002, The Journal of Immunology.

[34]  A. Fischer,et al.  Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study , 2002, The Lancet.

[35]  B. Blazar,et al.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.

[36]  N. Chao,et al.  Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. , 2002, Blood.

[37]  C. Huber,et al.  Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. , 2002, Blood.

[38]  R. Soiffer,et al.  The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. , 2001, Blood.

[39]  R. Noelle,et al.  Cd4+Cd25+ Immune Regulatory Cells Are Required for Induction of Tolerance to Alloantigen via Costimulatory Blockade , 2001, The Journal of experimental medicine.

[40]  Mark M. Davis,et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.

[41]  A. Zander,et al.  Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation‐induced antigens (CD25 and CD69) , 2000, British journal of haematology.

[42]  C. Fathman,et al.  Identification and characterization of the antigen-specific subpopulation of alloreactive CD4+ T cells in vitro and in vivo. , 2000, Transplantation.

[43]  L. Verdonck,et al.  Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft‐versus‐host disease , 1999, British journal of haematology.

[44]  W. M. Smit,et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. , 1999, Blood.

[45]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[46]  H. Prentice,et al.  Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis , 1999, Bone Marrow Transplantation.

[47]  F. Marini,et al.  Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations. , 1999, Transplantation.

[48]  C. Fathman,et al.  Following antigen challenge, T cells up-regulate cell surface expression of CD4 in vitro and in vivo. , 1998, Journal of immunology.

[49]  C. Bordignon,et al.  HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. , 1997, Science.

[50]  B. Rocha,et al.  T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. , 1997, Journal of immunology.

[51]  A. Barrett,et al.  Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. , 1994, Bone marrow transplantation.

[52]  A. Fischer,et al.  SPECIFIC ELIMINATION OF ALLOREACTIVE T CELLS BY AN ANTI‐INTERLEUKIN-2 RECEPTOR B CHAIN‐SPECIFIC IMMUNOTOXIN , 1990, Transplantation.

[53]  E. Aktas,et al.  Relationship between CD107a expression and cytotoxic activity. , 2009, Cellular immunology.

[54]  Shamsul A. Khan,et al.  Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  Shamsul A. Khan,et al.  Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. , 2007, Blood.

[56]  J. Ferrara,et al.  Pathophysiology of graft-versus-host disease. , 2006, Seminars in hematology.

[57]  M. Schilham,et al.  Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. , 2005, Human immunology.

[58]  P. Wallace,et al.  Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. , 2004, Methods in molecular biology.